Regeneron Pharmaceuticals (NASDAQ:REGN) launches the
first clinical trial evaluating REGN-COV2 (REGN10933 + REGN10987), its
dual antibody cocktail, for the prevention and treatment of COVID-19.
The clinical program will involve four
populations: hospitalized patients, non-hospitalized symptomatic
patients, uninfected people in groups at high risk of exposure and
uninfected people with close exposure to a COVID-19 patient.
The first two adaptive Phase 1/2/3 trials will
involve hospitalized and non-hospitalized patients with COVID-19.
Results from the Phase 1 & 2 portions will inform the endpoints and
size of the Phase 3s.
The company says the two antibodies bind
non-competitively to the critical receptor-binding domain of the
SARS-CoV-2 spike protein.
https://seekingalpha.com/news/3582201-regeneron-initiates-study-of-antibody-cocktail-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.